Business Context and Reporting Period
Company: American Vanguard Corporation (AMVAC Chemical Corporation, a wholly-owned subsidiary)
Filing Type: Form 8-K (Current Report)
Reporting Date: December 7, 2010 (Event Date); December 13, 2010 (Filing Date)
Context: The company entered into and completed definitive agreements to acquire specific insecticide product lines from Bayer CropScience Aktiengesellschaft.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific asset acquisition event rather than periodic financial performance.
Transaction Consideration: The purchase price for the acquired assets was determined through arm's-length negotiation but was not disclosed in this filing.
Material Changes
- Asset Acquisition: AMVAC acquired global rights to the insect product lines Mocap and Nemcur (excluding Europe and Argentina for Nemcur).
- Assets Included: Active ingredients (ethoprophos and fenamiphos), trademarks (Mocap, Nemacur, Ultima), registrations, registration data, manufacturing/formulation know-how, intellectual property rights, inventories, and the Ultima closed delivery system.
- Historical Context: This follows a previous acquisition of the tribufos product line from Bayer on July 21, 2010, continuing a decade-long commercial relationship between the parties.
Guidance, Outlook, and Risks
Management Commentary: The transaction was completed on December 7, 2010. A press release detailing the acquisition was issued on December 13, 2010.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies arising from this specific transaction, other than the standard legal disclaimer that the information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Unusual Items: None reported beyond the strategic asset acquisition.
Investor Verification Checklist
- Verify the undisclosed purchase price and payment terms in subsequent filings or the attached press release (Exhibit 99.1).
- Confirm the specific geographic exclusions for the Nemcur product line (Europe and Argentina).
- Review the impact of the acquired active ingredients (ethoprophos and fenamiphos) on the company's regulatory compliance and product portfolio.
- Assess the integration of the Ultima closed delivery system into existing operations.